Ultra-sensitive multiplex immunoassay technology now detects low-abundance biomarkers in complex matrices like cerebrospinal fluid, enabling earlier-stage Alzheimer’s and neurodegenerative disease research that simply wasn’t possible a few years ago. p-Tau 217 went from emerging marker to rapid clinical adoption. p-Tau 205 and APOE ε4 are right behind it.
Here’s what makes this category different from almost every other reagent and assay market: the gap between a published biomarker discovery and a validated, commercially available assay is shrinking fast. Researchers in this space want a usable assay shortly after a discovery is published, not after your team runs a standard multi-year product development cycle. Treat this market with the same timeline you’d use for a typical reagent launch, and a faster competitor will already own the early adopters by the time you ship.
Why being technically capable isn’t enough here
Most reagent and kit markets reward technical rigor and patience. This one rewards technical rigor and speed, together. That means your scientific team needs to be actively monitoring neurodegeneration and CNS literature to spot assay opportunities early, not waiting for customer requests to validate that a market exists. It means academic co-development partnerships tied to a specific new discovery can be worth more than a year of generic outbound prospecting. And it means your CRM and pipeline reporting need a faster review cadence than the quarterly check-in that works fine in slower-moving categories.
PSG Life Sciences works across the proteomics technologies market this category depends on, multiplex immunoassays, antibody discovery and validation platforms, ELISA systems, and the protein characterization work behind every new CNS biomarker panel. We help companies move from “we have validated science” to “we have a commercial product” faster than their internal default pace would otherwise allow.
Where PSG Life Sciences fits
Need to compress the time between biomarker validation and commercial launch? Our Start solution builds positioning and go-to-market content in parallel with your scientific validation work, instead of waiting until the assay is fully finished to start selling.
Selling across academic research, pharma translational, and diagnostic-stage buyers who all need different proof? Our Grow solution segments your CRM and content by buyer type, since a pharma translational buyer tied to a drug program’s clinical timeline needs a very different sales conversation than a diagnostic lab evaluating a long-term service line investment.
Need pipeline visibility that updates as fast as the science does? HubSpot Life Sciences Pro tracks time-from-publication-to-inquiry as a leading indicator, so you see market timing shift before it shows up in lagging revenue numbers.
What we actually build for CNS and neurodegeneration biomarker companies
- Compressed go-to-market timelines that run positioning and content development alongside scientific validation, not after it
- Buyer segmentation by academic research, pharma translational, and diagnostic stage, each with distinct proof points and sales cadences
- Academic co-development tracking, tied to specific published discoveries, as a deliberate early-mover channel rather than an opportunistic afterthought
- Granular biomarker and panel tracking in CRM, since the specific marker list in this category changes faster than in almost any other reagent market
- More frequent pipeline review cadence, because a biomarker that was niche six months ago may already be driving real lead volume today
A direct question worth asking yourself
The last time a major new CNS biomarker was published, how many weeks passed before your company had a go-to-market plan for it, and how many weeks did your fastest competitor take?
Ready to move at the speed this market actually requires?
PSG Life Sciences is a HubSpot Gold partner and fractional commercialization firm working exclusively with biotech, life science, and diagnostic product companies, including the proteomics and immunoassay platforms this market runs on. We build the compressed go-to-market systems described above as implemented client work, not theory.